PTCT PTC THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1070081 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-35.1%
TTM net income YoY-114.1%
TTM EPS YoY-115.5%
Revenue 3-yr CAGR13.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin12.8%
Net margin-9.2%
FCF margin0.2%
EBITDA margin18.1%
Returns
ROE—
ROA-3.6%
ROIC (approx.)—
Asset turnover0.39x
Leverage & solvency
Liabilities / assets106.0%
Debt / equity—
Current ratio3.27x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.10x
Accruals ratio-4.0%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $357.81M | $360.52M | $272.55M | $164.68M | $211.01M | $178.88M | $1.18B | $213.17M |
| R&D expense | $105.35M | $99.15M | $100.87M | $133.13M | $100.16M | $112.99M | $108.97M | $124.77M |
| SG&A expense | $80.08M | $80.63M | $86.18M | $96.87M | $84.05M | $85.26M | $80.96M | $84.68M |
| Operating income | $25.11M | $148.98M | $44.96M | -$71.35M | $3.02M | -$34.96M | $970.23M | -$162.39M |
| Pretax income | -$41.09M | $97.55M | -$2.46M | -$139.08M | -$23.07M | -$71.05M | $929.83M | -$94.70M |
| Income tax | $10.61M | $14.05M | $347,000 | -$4.12M | -$38.97M | -$6.20M | $63.27M | -$28.81M |
| Net income | -$51.69M | $83.50M | -$2.81M | -$134.97M | $15.90M | -$64.85M | $866.56M | -$65.89M |
| EBITDA | $41.93M | $164.85M | $60.37M | -$58.45M | $14.12M | -$27.37M | $977.45M | -$155.62M |
| EPS (basic) | -0.62 | 1.01 | -0.03 | — | 0.20 | -0.83 | 11.09 | — |
| EPS (diluted) | -0.62 | 0.92 | -0.03 | — | 0.20 | -0.83 | 10.04 | — |
| Weighted avg. shares (diluted) | 83.48M | 92.02M | 82.52M | — | 87.12M | 78.15M | 86.39M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $508.89M | $1.05B | $833.99M | $984.65M | $686.30M | $1.03B | $1.50B | $795.32M |
| Short-term investments | $1.62B | $1.18B | $1.06B | $960.72M | $1.02B | $971.76M | $546.95M | $359.99M |
| Receivables | $238.07M | $239.04M | $219.92M | $181.62M | $203.07M | $196.13M | $210.50M | $158.55M |
| Inventory | $109.33M | $91.35M | $75.57M | $79.65M | $52.69M | $34.06M | $21.68M | $23.19M |
| Current assets | $2.54B | $2.62B | $2.25B | $2.27B | $2.01B | $2.27B | $2.32B | $1.37B |
| PP&E, net | $49.33M | $51.49M | $52.74M | $55.37M | $56.97M | $57.19M | $59.46M | $60.97M |
| Goodwill | $82.34M | $82.34M | $82.34M | $82.34M | $82.34M | $82.34M | $82.34M | $82.34M |
| Intangibles | $443.69M | $402.93M | $380.68M | $388.75M | $396.47M | $143.81M | $118.45M | $118.79M |
| Total assets | $3.21B | $3.25B | $2.87B | $2.90B | $2.64B | $2.63B | $2.66B | $1.71B |
| Current liabilities | $776.08M | $771.07M | $923.60M | $968.43M | $866.25M | $627.81M | $595.39M | $580.98M |
| Short-term debt | — | $55.45M | $286.94M | $286.63M | $286.32M | — | — | — |
| Long-term debt | $536.27M | $535.52M | — | — | — | $286.01M | $285.71M | $285.41M |
| Total debt | $536.27M | $590.97M | — | — | — | $286.01M | $285.71M | $285.41M |
| Total liabilities | $3.40B | $3.42B | $3.05B | $3.10B | $2.80B | $2.84B | $2.84B | $2.80B |
| Shareholders' equity | -$191.21M | -$165.36M | -$180.47M | -$205.31M | -$155.76M | -$206.55M | -$185.76M | -$1.10B |
| Net debt | $27.37M | -$458.92M | — | — | — | -$747.06M | -$1.21B | -$509.90M |
| Shares outstanding | 83.54M | 83.33M | 82.88M | 81.47M | 79.93M | 79.38M | 79.23M | 77.70M |
| Cash flow statement | ||||||||
| Operating cash flow | -$25.31M | $129.11M | -$59.04M | -$34.27M | -$66.30M | -$58.33M | $870.10M | -$30.00M |
| Capital expenditure | $2.66M | $2.19M | $1.20M | $2.37M | $3.44M | $1.32M | $1.72M | $3.77M |
| Free cash flow | -$27.97M | $126.92M | -$60.24M | -$36.65M | -$69.75M | -$59.65M | $868.38M | -$33.77M |
| Investing cash flow | -$442.41M | -$122.56M | -$93.74M | $34.01M | -$289.62M | -$422.01M | -$184.36M | $267.71M |
| Financing cash flow | -$73.24M | $211.88M | $6.40M | $302.50M | $15.22M | $3.96M | $9.41M | $26.47M |
| Depreciation & amortization | $16.82M | $15.87M | $15.41M | $12.90M | $11.11M | $7.58M | $7.22M | $6.76M |
| Stock-based compensation | $23.83M | $23.29M | $23.42M | $18.52M | $19.43M | $18.54M | $18.06M | $17.24M |
Free plan shows the latest 8 periods; Pro shows all 59 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.